RAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Oliveras Salvá, Marusela ^a   Van Der Perren, Anke ^a   Casadei, Nicolas ^b   Stroobants, Stijn ^a   Nuber, Silke ^b,c   D'Hooge, Rudi ^a   Van Den Haute, Chris ^a   Baekelandt, Veerle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

A53T; AAV; Aggregation; Alpha synuclein; Behaviour; Model; Mouse; Neurodegeneration; Parkinson's disease; Phosphorylation

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; ENHANCED GREEN FLUORESCENT PROTEIN; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR SEROTYPE 2; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR SEROTYPE 7; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD TEST; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; ROTAROD TEST; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALIA; MUS; MUS MUSCULUS; PRIMATES; RATTUS;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84888119924     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-44     Document Type: Article

References (57)

1. Alpha-synuclein in Lewy bodies. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, Nature 1997 388 839 840 10.1038/42166 9278044 (Pubitemid 27377048)
2. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. Lancet 2004 364 1167 1169 10.1016/S0140-6736(04)17103-1 15451224 (Pubitemid 39296604)
3. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O, Nat Genet 1998 18 106 108 10.1038/ng0298-106 9462735
4. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Science 1997 276 2045 2047 10.1126/science.276.5321.2045 9197268 (Pubitemid 27443610)
5. alpha-Synuclein locus triplication causes Parkinson's disease. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. Science 2003 302 841 10.1126/science.1090278 14593171 (Pubitemid 37339619)
6. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. Ann Neurol 2004 55 164 173 10.1002/ana.10795 14755719 (Pubitemid 38166992)
7. Alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL, Acta Neuropathol 2013 125 5 753 769 10.1007/s00401-013- 1096-7 23404372
8. A novel alpha-synuclein missense mutation in Parkinson disease. Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH, Neurology 2013 80 1062 1064 10.1212/WNL.0b013e31828727ba 23427326
9. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A, Lancet 2004 364 1169 1171 10.1016/S0140-6736(04) 17104-3 15451225 (Pubitemid 39296605)
10. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al. Nat Genet 2009 41 1303 1307 10.1038/ng.485 19915576
11. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al. Nat Genet 2009 41 1308 1312 10.1038/ng.487 19915575
12. Modelling of Parkinson's disease in mice. Chesselet MF, Richter F, Lancet Neurol 2011 10 1108 1118 10.1016/S1474-4422(11)70227-7 22094131
13. alpha-Synucleinopathy models and human neuropathology: similarities and differences. Kahle PJ, Acta Neuropathol 2008 115 87 95 17932682 (Pubitemid 350238669)
14. Use of viral vectors to create animal models for Parkinson's disease. Low K, Aebischer P, Neurobiol Dis 2012 48 189 201 10.1016/j.nbd.2011.12.038 22227451
15. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Lauwers E, Beque D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, Casteels C, Vercammen L, Bockstael O, Nuttin B, et al. Neurobiol Aging 2007 28 248 257 10.1016/j.neurobiolaging.2005.12.005 16423428 (Pubitemid 44914019)
16. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V, Brain Pathol 2003 13 364 372 12946025 (Pubitemid 36975826)
17. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. Gerard M, Deleersnijder A, Daniels V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, et al. J Neurosci 2010 30 2454 2463 10.1523/JNEUROSCI.5983-09.2010 20164329
18. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V, Hum Gene Ther 2007 18 195 206 10.1089/hum.2006.178 17343566 (Pubitemid 46626459)
19. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Van der Perren A, Toelen J, Carlon M, Van den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z, Baekelandt V, Gene Ther 2011 18 517 527 10.1038/gt.2010.179 21326331
20. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ, Mol Ther 2007 15 1504 1511 10.1038/sj.mt.6300227 17565350 (Pubitemid 47103062)
21. Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE Jr, Mol Ther 2010 18 588 593 10.1038/mt.2009.286 20010918
22. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N, Mol Ther 2004 10 302 317 10.1016/j.ymthe.2004.05.024 15294177 (Pubitemid 39117875)
23. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A, J Neurosci 2002 22 2780 2791 11923443 (Pubitemid 37465827)
24. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H, J Neurochem 2004 91 451 461 10.1111/j.1471-4159.2004.02728.x 15447678 (Pubitemid 39363444)
25. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A, Neurobiol Dis 2012 45 939 953 10.1016/j.nbd.2011.12.013 22182688
26. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ, J Neuropathol Exp Neurol 2009 68 515 524 10.1097/NEN.0b013e3181a24b53 19525899
27. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M, PLoS One 2010 5 8784 10.1371/journal.pone.0008784 20098715
28. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM, Mol Neurodegener 2010 5 43 10.1186/1750-1326-5-43 21029459
29. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A, Proc Natl Acad Sci U S A 2003 100 2884 2889 10.1073/pnas.0536383100 12601150 (Pubitemid 36297593)
30. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T, Nat Cell Biol 2002 4 160 164 11813001
31. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al. J Biol Chem 2006 281 29739 29752 10.1074/jbc.M600933200 16847063 (Pubitemid 44536983)
32. Using recombinant adeno-associated viral vectors for gene expression in the brain. Van der Perren A, Toelen J, Taymans JM, Baekelandt V, Neuromethods 2012 65 47 68
33. Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Cao S, Theodore S, Standaert DG, Mol Neurodegener 2010 5 42 10.1186/1750-1326-5-42 20977765
34. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. Theodore S, Cao S, McLean PJ, Standaert DG, J Neuropathol Exp Neurol 2008 67 1149 1158 10.1097/NEN.0b013e31818e5e99 19018246
35. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ, J Neurochem 2007 100 1449 1457 17241127 (Pubitemid 46376202)
36. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. Dong Z, Ferger B, Feldon J, Bueler H, J Neurobiol 2002 53 1 10 10.1002/neu.10094 12360578
37. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Hattori N, Mizuno Y, Mochizuki H, J Neurochem 2009 108 932 944 10.1111/j.1471-4159.2008.05827.x 19141079
38. Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons. Ulusoy A, Bjorklund T, Buck K, Kirik D, Neurobiol Dis 2012 47 367 377 10.1016/j.nbd.2012.05.012 22659302
39. New recombinant serotypes of AAV vectors. Gao G, Vandenberghe LH, Wilson JM, Curr Gene Ther 2005 5 285 297 10.2174/1566523054065057 15975006 (Pubitemid 40895013)
40. Paxinos G, Franklin KBJ, The Mouse Brain in Stereotaxic Coordinates San Diego: Academic Press 2001
41. alpha-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment. George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG, J Mol Neurosci 2010 42 243 254 10.1007/s12031-010-9378-1 20464527
42. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z, Hum Gene Ther 2002 13 841 853 10.1089/10430340252899019 11975850 (Pubitemid 34493977)
43. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C, Baekelandt V, Mol Ther 2006 14 716 723 10.1016/j.ymthe.2006.06.009 16914382 (Pubitemid 44507714)
44. Design-based stereology in neuroscience. Schmitz C, Hof PR, Neuroscience 2005 130 813 831 10.1016/j.neuroscience.2004.08.050 15652981 (Pubitemid 40094616)
45. The efficiency of systematic sampling in stereology and its prediction. Gundersen HJ, Jensen EB, J Microsc 1987 147 229 263 10.1111/j.1365-2818.1987. tb02837.x 3430576
46. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG, J Biol Chem 2003 278 44405 44411 10.1074/jbc.M308041200 12923179 (Pubitemid 37377190)
47. Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Nuber S, Franck T, Wolburg H, Schumann U, Casadei N, Fischer K, Calaminus C, Pichler BJ, Chanarat S, Teismann P, et al. Neurogenetics 2010 11 107 120 10.1007/s10048-009-0212-2 19760259
48. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM, Brain 2009 132 1093 1101 19155272
49. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG, Brain Pathol 2012 22 745 756 10.1111/j.1750-3639.2012.00585.x 22369130
50. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Ulusoy A, Decressac M, Kirik D, Bjorklund A, Prog Brain Res 2010 184 89 111 20887871
51. Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. Burre J, Sharma M, Sudhof TC, J Neurosci 2012 32 15227 15242 10.1523/JNEUROSCI.3545-12.2012 23100443
52. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P, Hum Mol Genet 2009 18 872 887 19074459
53. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM, PLoS One 2011 6 17698 10.1371/journal.pone.0017698 21408191
54. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM, Hum Gene Ther 2010 21 1259 1271 10.1089/hum.2010.055 20497038
55. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D, Brain 2007 130 799 815 10.1093/brain/awl382 17303591 (Pubitemid 46410741)
56. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, et al. Acta Neuropathol 2012 123 653 669 10.1007/s00401-012-0963-y 22361813
57. Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M, Neuroscience 2012 208 85 96 22342967